
News|Articles|May 31, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 31, 2022
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, May 31, 2022, at 2:20 PM, EDT:
46.7% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
• 66.7% of total US population
• 70.8% of US population aged ≥5 years
• 75.1% of US population aged ≥12 years
• 76.6% of US population aged ≥18 years
• 91.1% of US population aged ≥65 years
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, May 31, 2022 at 5:20 PM, EDT, there have been:
• 84 133 468 confirmed cases and
• 1 006 909 deaths
• 1 006 909 deaths
In the past 28 days, the 3 states with the most new cases are:
1. California: 311 395
2. New York: 232 391
3. Florida: 182 392
2. New York: 232 391
3. Florida: 182 392
Deaths: California has the highest number of deaths due to COVID-19 with 91 313 reported fatalities, followed by Texas with 88 362 and Florida with 74 550.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 529 750 936 confirmed cases, 6 291 917 deaths, and 11 533 333 048 vaccine doses administered.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
2
Menopause Education Lags in Residency Training Across Primary Care Specialties
3
Treating Hot Flashes May Improve Cognitive Symptoms: Study Author Explains the Connection
4
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
5











































































































































































































































































































